These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26425550)

  • 1. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
    Cervantes-Madrid D; Romero Y; Dueñas-González A
    Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
    Lemberg KM; Vornov JJ; Rais R; Slusher BS
    Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and antitumor efficacy
    Cervantes-Madrid D; Dominguez-Gomez G; Gonzalez-Fierro A; Perez-Cardenas E; Taja-Chayeb L; Trejo-Becerril C; Duenas-Gonzalez A
    Oncol Lett; 2017 Mar; 13(3):1905-1910. PubMed ID: 28454342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids.
    Cervantes-Madrid D; Dueñas-González A
    Oncol Rep; 2015 Sep; 34(3):1533-42. PubMed ID: 26134042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic resurgence of 6-diazo-5-oxo-l-norleucine (DON) through tissue-targeted prodrugs.
    Novotná K; Tenora L; Slusher BS; Rais R
    Adv Pharmacol; 2024; 100():157-180. PubMed ID: 39034051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of inhibitors of glycolysis, glutaminolysis and
    Schcolnik-Cabrera A; Dominguez-Gómez G; Chávez-Blanco A; Ramírez-Yautentzi M; Morales-Bárcenas R; Chávez-Díaz J; Taja-Chayeb L; Dueáas-González A
    Oncol Lett; 2019 Dec; 18(6):6909-6916. PubMed ID: 31788130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children.
    Sullivan MP; Nelson JA; Feldman S; Van Nguyen B
    Cancer Chemother Pharmacol; 1988; 21(1):78-84. PubMed ID: 3342470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells.
    Schcolnik-Cabrera A; Chavez-Blanco A; Dominguez-Gomez G; Juarez M; Lai D; Hua S; Tovar AR; Diaz-Chavez J; Duenas-Gonzalez A
    Oncol Lett; 2020 Sep; 20(3):3053-3060. PubMed ID: 32782623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma.
    Rubin J; Sorensen S; Schutt AJ; van Hazel GA; O'Connell MJ; Moertel CG
    Am J Clin Oncol; 1983 Jun; 6(3):325-6. PubMed ID: 6846250
    [No Abstract]   [Full Text] [Related]  

  • 10. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
    Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
    Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force.
    De Marinis F; Rinaldi M; Ardizzoni A; Bruzzi P; Pennucci MC; Portalone L; D'Aprile M; Ripanti P; Romano F; Belli M; Altavilla G; Migliorino MR; Rosso R; Salvati F
    Tumori; 1999; 85(3):177-82. PubMed ID: 10426128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas.
    Earhart RH; Amato DJ; Chang AY; Borden EC; Shiraki M; Dowd ME; Comis RL; Davis TE; Smith TJ
    Invest New Drugs; 1990 Feb; 8(1):113-9. PubMed ID: 2188926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of
    Novotná K; Tenora L; Prchalová E; Paule J; Alt J; Veeravalli V; Lam J; Wu Y; Šnajdr I; Gori S; Mettu VS; Tsukamoto T; Majer P; Slusher BS; Rais R
    J Med Chem; 2023 Nov; 66(22):15493-15510. PubMed ID: 37949450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial with and without lonidamine in non-small cell lung cancer.
    Gatzemeier U; Cavalli F; Häussinger K; Kaukel E; Koschel G; Martinelli G; Neuhauss R; von Pawel J
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):42-8. PubMed ID: 1851577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-asparaginase and 6-diazo-5-oxo-L-norleucine synergistically inhibit the growth of glioblastoma cells.
    Ohba S; Hirose Y
    J Neurooncol; 2020 Feb; 146(3):469-475. PubMed ID: 32020477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.
    Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM
    Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma.
    Rais R; Jančařík A; Tenora L; Nedelcovych M; Alt J; Englert J; Rojas C; Le A; Elgogary A; Tan J; Monincová L; Pate K; Adams R; Ferraris D; Powell J; Majer P; Slusher BS
    J Med Chem; 2016 Sep; 59(18):8621-33. PubMed ID: 27560860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro.
    Griffiths M; Keast D; Patrick G; Crawford M; Palmer TN
    Int J Biochem; 1993 Dec; 25(12):1749-55. PubMed ID: 8138012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine.
    Bhutia YD; Babu E; Ganapathy V
    Biochem J; 2016 Jun; 473(11):1503-6. PubMed ID: 27234586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
    Sklaroff RB; Casper ES; Magill GB; Young CW
    Cancer Treat Rep; 1980; 64(12):1247-51. PubMed ID: 7471114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.